Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Thelansis's analysts note that the MCRPC patient segment is highly competitive because of the availability of multiple treatments. However, opportunities exist for novel therapies that can extend the overall survival for these patients beyond the efficacy of current therapies. Below highlighted are some key opportunities for drug development in prostate cancer, based on KOL insights: Thelansis's analysts note that the MCRPC patient segment is highly competitive because of the availability of...

Thelansis's analysts note that the MCRPC patient segment is highly competitive because of the availability of multiple treatments. However, opportunities exist for novel therapies that can extend the overall survival for these patients beyond the efficacy of current therapies. Below highlighted are some key opportunities for drug development in prostate cancer, based on KOL insights:

Key opportunities for drug development / unmet needs:

MCRPC patients: Novel therapies with better overall survival than current treatments

Precision medicines: Needs for precision medicines with biomarkers for better response rates in subpopulations.

Combination therapies: Need for combination regimens for treatment optimization.

Successfully targeting these opportunities would differentiate a novel emerging drug in prostate cancer, and would enable faster sales and patient share uptake. Some late-phase emerging agents targeting one or the other opportunities include,

 

KOL perspectives:

"I believe that we need a cure for the castrate-resistant prostate cancer. But that's not possible without individualized treatments." - A leading U.S.-based oncologist

"An LHRH agonist is the SOC for MCRC patients. These drugs are continued till the death of the patient. We should probably continue the next-generation hormonal treatment. However, data is limited for the long-term benefits for maintaining both the treatments."  - A leading Europe-based oncologist

Closing statement:

Thelansis's report on prostate cancer provides in-depth insights on the commercially relevant patient segments for prostate cancer, along with the drug development pipeline for these segments. In addition, the report answers key questions such as,

About Thelansis

Thelansis specializes in providing business research, data analytics, and consulting services to pharmaceutical/ biopharmaceutical companies globally. Over the period of decades into domain research, we have built a robust repository of 6,000+ bio-pharma reports covering epidemiology studies, market forecasting, and opportunity assessment based on KOL interviews and conference coverage. Our competitive intelligence and conference coverage throughout the phases of asset development were executed by a team with a mix of scientific and business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

We provide consulting-grade market research reports and business solutions using our worldwide delivery model for many clients, including multinational biopharma innovator companies and mid-cap and small-cap. We have deep expertise in Competitive Intelligence, Primary Market Research (PMR), Secondary Research, Forecasting, and Data Analytics, leveraging technology across these functional areas.

Offerings in oncology indications: syndicated reports/offerings for the major markets, epidemiology, customized market research including KOL interviews, PMR surveys, pipeline research, conference coverage, market forecast models, and consulting.

The developers for oncology agents can engage Thelansis for customized market research and can gain on possible solutions for ensuring considerable market penetration for their respective therapies.

Contact us today on ….

Website: Thelansis.com 
For more information, please contact:
Chinmaya Kumar Senapati
Email- clientsupport@thelansis.com
Contact No: +91- 6397-349664

Logo: https://mma.prnewswire.com/media/2336260/THELANSIS_LOGO.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/prostate-cancer---market-outlook-epidemiology-competitive-landscape-and-market-forecast-report-2023-to-2033-302088446.html